GlassScriptPhysician profile
Susan A Mathew
NPI 1356651244
$56,385.83
in general payments reported to CMS, 2019-2025
35 companies · $2,686 in 2025
The $2,686 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $7,917 · 2021: $5,317 · 2022: $5,033 · 2023: $3,488 · 2024: $11K · 2025: $2,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,453 · Consulting Fee: $6,265 · Travel and Lodging: $1,452 · Education: $91.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,452.57 |
| Consulting Fee | $6,265.00 |
| Travel and Lodging | $1,451.67 |
| Education | $91.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $17,499.01 | 2019 | |
| Mallinckrodt Hospital Products INC. | $12,384.35 | 2020-2025 | Acthar |
| Ucb, INC. | $7,295.04 | 2019-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $4,244.94 | 2019-2025 | |
| Janssen Biotech, INC. | $2,962.50 | 2019-2025 | Tremfya |
| Amgen INC. | $2,557.07 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Pfizer INC. | $1,356.06 | 2019-2025 | |
| Horizon Therapeutics Plc | $1,352.31 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $1,110.90 | 2019-2025 | |
| Lilly USA, LLC | $875.00 | 2019-2025 | Taltz, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $636.74 | 2019-2025 | Benlysta, Nucala |
| Astrazeneca Pharmaceuticals LP | $570.45 | 2021-2025 | Saphnelo |
| Nevro Corp. | $390.52 | 2019-2024 | Senza |
| Aurinia Pharma U.S., INC. | $382.99 | 2021-2025 | Lupkynis |
| Genzyme Corporation | $364.45 | 2019-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $361.29 | 2019-2025 | Orencia, Sotyktu |
| Radius Health, INC. | $353.07 | 2019-2024 | Tymlos |
| Ani Pharmaceuticals, INC. | $282.68 | 2024-2025 | Purified Cortrophin Gel |
| Celgene Corporation | $281.96 | 2019 | |
| Alexion Pharmaceuticals, INC. | $215.53 | 2021-2025 | Strensiq |
| Medtronic, INC. | $145.88 | 2022-2025 | Intellis Adaptivestim |
| Johnson & Johnson Health Care Systems INC. | $129.09 | 2023 | Tremfya |
| Medexus Pharma, INC. | $127.54 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $120.41 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.43 | 2023-2025 | Cyltezo |
| Kiniksa Pharmaceuticals, LTD. | $51.79 | 2023 | Arcalyst |
| Sandoz INC. | $45.06 | 2023 | Hyrimoz |
| Gilead Sciences, INC. | $43.22 | 2020 | |
| Genentech USA, INC. | $39.36 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $24.58 | 2022 | |
| Sobi, INC | $19.53 | 2019 | |
| Celltrion USA INC. | $16.24 | 2023 | Yuflyma |
| Bioventus LLC | $15.24 | 2024 | Durolane |
| Ibsa Pharma INC. | $14.06 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.